Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALC CalciMedica	$2.91 +11.5%	$2.36	$1.42 ▼ $5.97	$40.66M	1.33	104,670 shs	28,763 shs
CGEN Compugen	$1.43 -1.4%	$1.60	$1.13 ▼ $2.66	$129.39M	2.61	223,863 shs	117,039 shs
CTOR Citius Oncology	$1.69 -1.7%	$2.43	$0.55 ▼ $6.19	$134.80M	3	1.55 million shs	59,776 shs
KYTX Kyverna Therapeutics	$3.51 -0.8%	$3.44	$1.78 ▼ $8.78	$153.09M	3.05	232,469 shs	284,589 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALC CalciMedica	+11.49%	+6.20%	+33.49%	+45.50%	-35.76%
CGEN Compugen	-1.38%	-4.67%	-9.49%	+2.88%	-18.29%
CTOR Citius Oncology	-1.74%	-6.63%	+7.64%	+84.70%	-31.58%
KYTX Kyverna Therapeutics	-0.85%	+8.33%	-13.76%	+51.29%	-48.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CALC CalciMedica	3.5274 of 5 stars	3.5	5.0	3.0	3.3	0.0
CGEN Compugen	1.9866 of 5 stars	3.5	3.0	2.6	0.0	0.0
CTOR Citius Oncology	1.655 of 5 stars	3.0	0.0	2.8	1.7	0.0
KYTX Kyverna Therapeutics	2.7294 of 5 stars	3.6	2.0	3.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALC CalciMedica	3.00	Buy	$16.00	449.83% Upside
CGEN Compugen	3.00	Buy	$4.00	179.72% Upside
CTOR Citius Oncology	2.00	Hold	$3.00	77.51% Upside
KYTX Kyverna Therapeutics	3.17	Buy	$15.60	344.44% Upside

Current Analyst Ratings Breakdown

Latest CALC, CGEN, CTOR, and KYTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $5.00
5/23/2025	CTOR Citius Oncology	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
5/23/2025	CTOR Citius Oncology	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALC CalciMedica	N/A	N/A	N/A	N/A	$0.44 per share	N/A
CGEN Compugen	$27.86M	4.58	N/A	N/A	$0.56 per share	2.55
CTOR Citius Oncology	N/A	N/A	N/A	N/A	$0.41 per share	N/A
KYTX Kyverna Therapeutics	$7.03M	21.59	N/A	N/A	$4.26 per share	0.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALC CalciMedica	-$13.70M	-$1.60	N/A	N/A	N/A	N/A	-206.51%	-103.81%	N/A
CGEN Compugen	-$14.23M	-$0.22	N/A	N/A	N/A	-87.45%	-34.77%	-16.82%	N/A
CTOR Citius Oncology	N/A	N/A	0.00	∞	N/A	N/A	-51.93%	-22.17%	N/A
KYTX Kyverna Therapeutics	-$127.48M	-$3.68	N/A	N/A	N/A	N/A	-64.98%	-56.17%	N/A

Latest CALC, CGEN, CTOR, and KYTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	CALC CalciMedica	-$0.40	-$0.40	N/A	-$0.40	N/A	N/A
8/12/2025	Q2 2025	KYTX Kyverna Therapeutics	-$1.00	-$0.97	+$0.03	-$0.97	N/A	N/A
8/6/2025	Q2 2025	CGEN Compugen	-$0.07	-$0.08	-$0.01	-$0.08	$3.95 million	$1.26 million
5/19/2025	Q1 2025	CGEN Compugen	-$0.06	-$0.08	-$0.02	-$0.08	$3.70 million	$2.28 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALC CalciMedica	N/A	N/A	N/A	N/A	N/A
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
CTOR Citius Oncology	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALC CalciMedica	1.39	5.45	5.66
CGEN Compugen	N/A	4.74	4.74
CTOR Citius Oncology	0.12	0.35	0.05
KYTX Kyverna Therapeutics	N/A	5.39	7.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALC CalciMedica	N/A
CGEN Compugen	12.22%
CTOR Citius Oncology	70.52%
KYTX Kyverna Therapeutics	18.08%

Insider Ownership

Company	Insider Ownership
CALC CalciMedica	41.55%
CGEN Compugen	9.50%
CTOR Citius Oncology	4.57%
KYTX Kyverna Therapeutics	22.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALC CalciMedica	30	13.97 million	8.17 million	No Data
CGEN Compugen	70	89.24 million	80.76 million	Optionable
CTOR Citius Oncology	N/A	78.37 million	74.79 million	N/A
KYTX Kyverna Therapeutics	96	43.25 million	33.73 million	Optionable

CALC, CGEN, CTOR, and KYTX Headlines

Recent News About These Companies

Kyverna Therapeutics (NASDAQ:KYTX) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

August 14 at 4:51 PM | marketbeat.com

Kyverna Therapeutics, Inc.: Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

August 13 at 9:47 AM | finanznachrichten.de

Kyverna Therapeutics reports Q2 EPS (97c), consensus ($1.04)

August 12, 2025 | msn.com

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

August 12, 2025 | globenewswire.com

Kyverna Therapeutics (KYTX) to Release Quarterly Earnings on Monday

August 10, 2025 | americanbankingnews.com

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $15.60 Consensus PT from Analysts

August 7, 2025 | americanbankingnews.com

Kyverna Therapeutics (KYTX) Expected to Announce Earnings on Monday

August 5, 2025 | marketbeat.com

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Recommendation of "Buy" from Brokerages

August 4, 2025 | marketbeat.com

Kyverna Appoints New CFO to Guide Next Growth Phase

July 29, 2025 | msn.com

Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise

July 29, 2025 | prnewswire.com

KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

July 2, 2025 | globenewswire.com

Kyverna Therapeutics Names Marc Grasso Chief Financial Officer

June 30, 2025 | marketwatch.com

Kyverna Therapeutics Announces Appointment of New Chief Financial Officer

June 30, 2025 | finance.yahoo.com

Kyverna Therapeutics (NASDAQ:KYTX) Activity Grows on Nasdaq Composite, Russell 1000

June 27, 2025 | kalkinemedia.comK

3 Promising Penny Stocks With Market Caps Over $100M

June 10, 2025 | finance.yahoo.com

Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference

May 28, 2025 | prnewswire.com

HC Wainwright & Co. Upgrades Kyverna Therapeutics (KYTX)

May 27, 2025 | msn.com

Kyverna Therapeutics: Buy Rating Backed by Promising Pipeline and Strong Financial Position

May 27, 2025 | tipranks.com

Kyverna Shareholder Sues Over Kidney Therapy Trial Data Post IPO

May 15, 2025 | news.bloomberglaw.comN

With 40% ownership, Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has piqued the interest of institutional investors

May 15, 2025 | finance.yahoo.com

KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

May 15, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CALC, CGEN, CTOR, and KYTX Company Descriptions

CalciMedica NASDAQ:CALC

$2.91 +0.30 (+11.49%)

Closing price 08/15/2025 03:59 PM Eastern

Extended Trading

$2.88 -0.03 (-1.03%)

As of 08/15/2025 07:11 PM Eastern

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Compugen NASDAQ:CGEN

$1.43 -0.02 (-1.38%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.44 +0.01 (+0.98%)

As of 08/15/2025 07:48 PM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Citius Oncology NASDAQ:CTOR

$1.69 -0.03 (-1.74%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.72 +0.03 (+1.48%)

As of 08/15/2025 07:53 PM Eastern

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Kyverna Therapeutics NASDAQ:KYTX

$3.51 -0.03 (-0.85%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$3.63 +0.12 (+3.39%)

As of 08/15/2025 06:09 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time